First-of-Its-Kind Implant Offers New Approach to Treating Rheumatoid Arthritis

November 19, 2026
SetPoint device
  • The SetPoint System is the first FDA-approved implantable device for treating rheumatoid arthritis, offering a novel non-medication approach to treating the painful condition.
  • Henry Ford Health began offering the treatment this fall after the neurosurgery team performed the state's first commercial implantation on Oct. 26 at Henry Ford Hospital in Detroit.
  • The device is implanted on the vagus nerve through a small incision in the neck. Once activated, it automatically delivers 60 seconds of electrical stimulation daily to control inflammation.

DETROIT — A new treatment for rheumatoid arthritis that uses a small, implanted device to help control inflammation is now available to patients in Michigan through Henry Ford Health's neurosurgery team.

The wireless device, about the size of a multivitamin, is implanted on the vagus nerve and uses electrical stimulation to activate the body's natural response to inflammation, helping ease the inflammation that causes joint pain, swelling and stiffness in rheumatoid arthritis.

Dr. Ellen Air, functional neurosurgeon and chair of the Department of Neurosurgery at Henry Ford Health, completed the state's first commercial implantation of the device on Oct. 26 at Henry Ford Hospital in Detroit. The patient, Kim Landrith, 71, of Macomb County, had the device activated Nov. 11.

"Vagus nerve stimulation has been used for years to treat conditions like epilepsy and in stroke recovery, and now we're applying this approach in a new way to help people with rheumatoid arthritis," said Dr. Air, who also served as an investigator in the pivotal clinical trial evaluating the SetPoint System. "For patients who haven't found relief with medications, this gives us a new way to treat the inflammation driving the disease, one that we hope can make a meaningful difference in how they feel and function every day."

New option for rheumatoid arthritis

Developed by California-based medical technology company SetPoint Medical, the SetPoint System is the first FDA-approved device of its kind for adults with moderate to severe rheumatoid arthritis who have had an inadequate response to medications or cannot tolerate them.

Kim Landrith

Rheumatoid arthritis is a chronic autoimmune disease that affects about 1.5 million people in the U.S. The disease causes the immune system to mistakenly attack healthy tissue in the joints, leading to inflammation, pain, swelling and stiffness that can make everyday activities difficult. Over time, it can permanently damage the joints and limit mobility.

While medications can help manage symptoms, some patients do not respond well, experience unwanted side effects or find that a medication that once worked becomes less effective over time.

Landrith, Henry Ford Health's first patient to receive the implant, has experienced those challenges firsthand. During nearly three decades with rheumatoid arthritis, she has tried a wide range of treatments to manage her symptoms, from oral medications and injections to infusion therapy and at-home remedies. Over the years, she has also undergone numerous joint replacement surgeries involving her knees, shoulders and hip. Today, pain and stiffness in her hands and feet persist, sometimes requiring her to use a cane.

"I'm hoping for more mobility and less pain," Landrith said shortly after her device was activated. "I want to be able to move my hands and fingers, to write my name and to walk without my toes and feet hurting. I used to love to cook and bake, and right now, it's difficult just to pick up a heavy pan or put cookie sheets in the oven."

What patients can expect

Dr. Ellen AirPatients eligible for the SetPoint System are typically referred by their rheumatologist to a neurosurgeon for implantation. The neurosurgeon places the device on the left vagus nerve through a small incision along a crease in the neck. The outpatient procedure takes about 60 to 90 minutes, and patients typically return home the same day.

A few weeks later, after the incision has healed, the device is activated during a follow-up appointment with the patient's rheumatologist. It then automatically delivers one minute of electrical stimulation each day, often while the patient is sleeping. Patients recharge the device weekly using a charger worn around the neck. It is designed to last up to 10 years.

Clinical studies found that patients with the implant showed improvements in their rheumatoid arthritis after three months. After one year, about half had achieved low disease activity or remission, and more than 75% had not needed to add another medication to their treatment. These findings helped support FDA approval of the SetPoint System in July 2025.

The treatment may also have long-term economic benefits. An analysis co-authored by Dr. Air projected that over the course of a lifetime, the therapy could reduce health care costs by more than $350,000 per patient compared with medication alone.

Patients interested in the SetPoint System are encouraged to talk with their rheumatologist about their eligibility and a possible referral to Henry Ford Health Neurosurgery.

###

MEDIA CONTACT: mediarelations@hfhs.org

Cookie Consent

We use cookies to improve your website experience. By using this site, you agree to our Terms of Use. Read our Internet Privacy Statement  to learn what information we collect and how we use it.

Accept All
Dismiss